Moreover, the glutaminase inhibitor JHU-083, a pro-drug that can penetrate the blood–brain barrier and is converted into 6-diazo-5-oxy-L-norleucin, caused a marked reduction in cell proliferation and downregulation of the mTOR pathway in animal models of IDH1-mutant gliomas [50]. Here, GLS is linked to central nervous system cancer.